» Articles » PMID: 26879560

Evidence of Misclassification of Drug-Event Associations Classified As Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP)

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 2016 Feb 17
PMID 26879560
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Pharmacovigilance includes analysis of large databases of information on drugs and events using algorithms that detect disproportional frequencies of associations. In order to test such algorithms, attempts have been made to provide canonical reference lists of so-called 'positive controls' and 'negative controls'. Reference sets with even modest levels of misclassification may result in under- or overstatement of the performance of algorithms.

Aim: We sought to determine the extent to which 'negative control' drug-event pairs in the Observational Medical Outcomes Partnership (OMOP) database are misclassified

Methods: We searched the medical literature for evidence of associations between drugs and events listed by OMOP as negative controls.

Results: The criteria used in OMOP to classify positive and negative controls are asymmetric; drug-event associations published only as case series or case reports are classified as positive controls if they are cited in Drug-Induced Diseases by Tisdale and Miller, but as negative controls if case series or case reports exist but are not cited in Tisdale and Miller. Of 233 drug-event pairs classified in the 2013 version of OMOP as negative controls, 21 failed to meet pre-specified OMOP adjudication criteria; in another 19 cases we found case reports, case series, or observational evidence that the drug and event are associated. Overall, OMOP misclassified, or may have misclassified, 40 (17 %) of all 'negative controls.'

Conclusions: Results from studies of the performance of signal-detection algorithms based on the OMOP gold standard should be viewed with circumspection, because imperfect gold standards may lead to under/overstatement of absolute and relative signal detection algorithm performance. Improvements to OMOP would include omitting misclassified drug-event pairs, assigning more specific event labels, and using more extensive sources of information.

Citing Articles

A real-world pharmacovigilance study on cardiovascular adverse events of tisagenlecleucel using machine learning approach.

Jung J, Kim J, Bae J, Woo S, Lee H, Shin J Sci Rep. 2024; 14(1):13641.

PMID: 38871843 PMC: 11176352. DOI: 10.1038/s41598-024-64466-x.


Implementation of a Taxonomy-Based Framework for the Selection of Appropriate Drugs and Outcomes for Real-World Data Signal Detection Studies.

Coste A, Wong A, Warren-Gash C, Matthewman J, Bate A, Douglas I Drug Saf. 2023; 47(2):183-192.

PMID: 38093083 PMC: 10821990. DOI: 10.1007/s40264-023-01382-5.


Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions.

Kontsioti E, Maskell S, Pirmohamed M Pharmacoepidemiol Drug Saf. 2023; 32(8):832-844.

PMID: 36916014 PMC: 10947279. DOI: 10.1002/pds.5609.


A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation.

Lee S, Lee J, Kim G, Kim J, Shin H, Ko I J Med Internet Res. 2022; 24(10):e35464.

PMID: 36201386 PMC: 9585444. DOI: 10.2196/35464.


Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system.

Lee J, Kim J, Bae J, Song I, Shin J Sci Rep. 2022; 12(1):14869.

PMID: 36050484 PMC: 9436954. DOI: 10.1038/s41598-022-18522-z.


References
1.
Worm S, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F . Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2009; 201(3):318-30. DOI: 10.1086/649897. View

2.
Pusey C, Rainford D . St Anthony's fire and pseudochronic renal failure. Br Med J. 1977; 2(6092):935. PMC: 1631626. DOI: 10.1136/bmj.2.6092.935. View

3.
Gonlusen G, Akgun H, Ertan A, Olivero J, Truong L . Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch Pathol Lab Med. 2006; 130(1):101-6. DOI: 10.5858/2006-130-101-RFANAW. View

4.
Weir M, Beyea M, Gomes T, Juurlink D, Mamdani M, Blake P . Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011; 171(7):703-4. DOI: 10.1001/archinternmed.2011.103. View

5.
Hennessy S, Leonard C . Comment on: "Desideratum for evidence-based epidemiology". Drug Saf. 2014; 38(1):101-3. DOI: 10.1007/s40264-014-0252-x. View